Abstract:
The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyzes. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.
Abstract:
Disclosed are a method for rapid screening suitable translational fusion partners (TFPs) capable of inducing expression or secretory production of non-producible proteins, which are difficult to produce in conventional recombinant production methods, from a variety of genetic sources, and protein secretion-inducing TFPs obtained using the method.
Abstract:
The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.
Abstract:
The invention relates to techniques for the rapid screening of suitable translational fusion partners (TFPs) capable of inducing secretory production of recombinant proteins, especially proteins that are difficult to produce using conventional recombinant production methods.
Abstract:
The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyses. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.
Abstract:
Disclosed are a method for rapid screening suitable translational fusion partners (TFPs) capable of inducing expression or secretory production of non-producible proteins, which are difficult to produce in conventional recombinant production methods, from a variety of genetic sources, and protein secretion-inducing TFPs obtained using the method.
Abstract:
A method and a kit for cloning a nucleotide sequence adjacent to a known nucleotide sequence by PCR are disclosed. The method includes 1) preparing a DNA fragment with cohesive ends by cleaving a DNA that contains the known first nucleotide sequence and the second nucleotide sequence adjacent thereto using a restriction enzyme; 2) modifying the 3′ end of the DNA fragment with a nucleotide analog to block further elongation of the DNA fragment; 3) linking the cohesive ends of the 3′ end-modified DNA fragment with a linker, adapter or cassette having a cohesive end sequence complementary thereto; and 4) performing PCR using a known first nucleotide sequence-specific primer, and a linker, adapter or cassette sequence-specific primer.
Abstract:
The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.
Abstract:
The invention relates to techniques for the rapid screening of suitable translational fusion partners (TFPs) capable of inducing secretory production of recombinant proteins, especially proteins that are difficult to produce using conventional recombinant production methods.
Abstract:
A method and a kit for cloning a nucleotide sequence adjacent to a known nucleotide sequence by PCR are disclosed. The method includes 1) preparing a DNA fragment with cohesive ends by cleaving a DNA that contains the known first nucleotide sequence and the second nucleotide sequence adjacent thereto using a restriction enzyme; 2) modifying the 3′ end of the DNA fragment with a nucleotide analogue to block further elongation of the DNA fragment; 3) linking the cohesive ends of the 3′ end-modified DNA fragment with a linker, adapter or cassette having a cohesive end sequence complementary thereto; and 4) performing PCR using a known first nucleotide sequence-specific primer, and a linker, adapter or cassette sequence-specific primer.